{"schema_version":"secwatch.filing_event.v1","accession":"0001127537-24-000073","form_type":"8-K","ticker":"LUNG","cik":"0001127537","company_name":"Pulmonx Corp","filed_at":"2024-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.238542+00:00","generated_at":"2026-05-31T14:15:55.672085+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pulmonx reports record Q2 revenue $20.8M (+21% YoY); net loss narrows to $15.3M","bullets":["Worldwide revenue $20.8M, up 21% YoY; U.S. revenue $13.9M (+26%); International $6.9M (+12%).","Net loss $15.3M ($0.39/share) vs $16.2M ($0.43) in Q2 2023; adjusted EBITDA loss $7.6M vs $10.3M.","Gross margin held at 74%; operating expenses $30.9M, including $1.7M one-time software impairment.","Added 17 new U.S. Zephyr Valve treatment centers; first U.S. patients treated in AeriSeal CONVERT II trial.","Full-year 2024 guidance reaffirmed: revenue $81-84M, gross margin 74-75%, opex $127-129M."],"urls":{"canonical":"https://secwatch.observer/filing/0001127537-24-000073","json":"https://secwatch.observer/filing/0001127537-24-000073.json","markdown":"https://secwatch.observer/filing/0001127537-24-000073.md","text":"https://secwatch.observer/filing/0001127537-24-000073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1127537/000112753724000073/0001127537-24-000073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1127537/000112753724000073/lung-20240731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:15:55.672085+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}